Patrick Serruys
Patrick W. Serruys (1947-)
In 2005 he held the 4th International Lecture at the AHA and Mikamo Lecture at the Japanese heart Association.
In 2006 he received the highest award of the Clinical Council of the American Heart Association: the James Herrick Award. In 2007 he received the Arrigo Recordati International Prize (Italy) and the ICI Achievement Award (bestowed by the President of Israel – Shimon Perez). In 2008 he received the Einthoven Penning (Leiden). In 2009 he became Doctor Honoris Causa from the University of Athens.
In 2011 he received the Lifetime Achievement Award, bestowed by the American College of Cardiology, in recognition of many years of service and invaluable contributions to the ACC. At the end of 2011 Dr Serruys received the Ray C. Fish Award, bestowed by the Texas Heart Institute, for outstanding achievement and contribution to cardiovascular medicine.
Diplomas
| Year | Diploma |
|---|---|
| 1965 - 1968 | Pre clinical medical studies, summa cum laude - University of Leuven, Belgium |
| 1968 - 1972 | Clinical studies, summa cum laude - University of Leuven, Belgium |
| 1972 | Internal medicine examination, Second of 29 candidates - University of Leuven, Belgium |
| 1972 | Medical degree, summa cum laude, Dux of class of 313 candidates |
| 1972 - 1973 | Internship. Rotations in internal and pulmonary medicine - University of Leuven, Belgium |
| 1973 | Rotation in hematology - University of Leuven, Belgium |
| 1973 - 1975 | Rotation in the intensive care and coronary care units. Prof. Tremouroux - University of Leuven, Belgium |
| 1975 | Cardiac surgery and post operative care. Prof. Chalant - University of Leuven, Belgium |
| 1975 - 1976 | Department of Cardiology. Prof. Basseur - University of Leuven, Belgium |
| 1976 | Department of Cardiology. Prof. Kremer - University of Leuven, Belgium |
| 1976 - 1985 | Department of Cardiology. Prof. Hugenholtz - Erasmus University, Rotterdam, The Netherlands. Certification as Cardiologist in Belgium and The Netherlands |
Clinical career
| Year | Function + center |
|---|---|
| 1977 | Senior Member of Cardiology Staff of the Thoraxcenter, Prof. Hugenholtz - Erasmus University, Rotterdam, The Netherlands |
| 1977 - 1980 | Co director of the Catheterization Laboratory, Thoraxcenter - Erasmus University, Rotterdam, The Netherlands |
| 1980 | Present Director of the Clinical Research Program of the Catheterization Laboratory and the Clinical Imaging Laboratory for angiography |
| 1983 | Correspondent of the French Society of Cardiology |
| 1984 | Chairman of the Working Group on Coronary Blood Flow and Angina Pectoris (European Society of Cardiology) |
| 1986 | Appointed to \"Chef de Clinique\", and defended cum laude his PhD thesis on: Transluminal coronary angioplasty: an investigational tool and a non operative treatment of acute myocardial ischemia |
| 1988 | Nomination as professor of interventional cardiology ("hoogleraar in interventie cardiologie") in the Interuniversity Cardiological Institute of the Netherlands (ICIN) |
| 1997 | Head of the Interventional Dept. Heartcenter Rotterdam, The Netherlands |
Latest contributions
Align for the future with the novel balloon expandable Myval transcatheter heart valve series
26 Nov 2024 – From PCR London Valves 2024
Watch this session to explore expert insights into best-in-class TAVI practices, from pre-procedural imaging and treatment strategy to procedural tips and post-procedural management. Learn from a compelling case study of an 88-year-old male patient with severe symptomatic aortic stenosis treated with the innovative MyVal Octapro THV....
Featured research - Aortic valve (Part 10)
26 Nov 2024 – From PCR London Valves 2024
Explore the latest research and insights in the field of aortic valve interventions through this featured research session. Discover cutting-edge studies on topics ranging from one-year outcomes after TAVI in different valve types to the impact of frailty and mobility on post-TAVI outcomes, and much more....
Align for the future with Myval THV series - From randomised trials to everyday clinical practice
25 Nov 2024 – From PCR London Valves 2024
Through the presentation of several compelling cases, including an 88-year-old male with CKD, RBBB, moderate LV dysfunction, and severe aortic stenosis, a Type 1a bicuspid native AS, and an extraordinary TAVI in an 83-year-old with acute heart failure and comorbidities, this session will dive into the...
The LANDMARK RCT: key findings and relevance in clinical practice
15 May 2024 – From EuroPCR 2024
Join Patrick Serruys, Niels Van Royen, and Andreas Baumbach in a roundtable discussing the LANDMARK RCT trial, a randomized comparison of three valves aiming to validate the Myval balloon-expandable THV. Explore the trial's methodology, clinical outcomes, and findings on this new intermediate-size device, which offers adaptability...
Comparative insights into QFR, FFR, and angiography
16 May 2024 – From EuroPCR 2024
This session, comprising selected EuroPCR 2024 Abstract submissions, focuses on various aspects of assessing and managing multivessel coronary artery disease. It includes presentations and discussions on the use of quantitative flow ratio (QFR) for assessing non-culprit lesions in acute myocardial infarction, functional assessment of surgical revascularization,...
REC-CAGEFREE II, NOTION-2, LANDMARK: Three major late-breaking trials presented at EuroPCR 2024
15 May 2024
The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice.
Align for the future with next-generation balloon expandable THV technology
15 May 2024 – From EuroPCR 2024
In this session, explore the next-generation balloon-expandable Myval Octacor THV, focusing on its key features, procedural impact, and potential clinical benefits. Understand the procedural steps for planning and implanting it, especially for intermediate and extra-large sizes, using the Octalign technique. Learn about the unmet clinical need...
Major Late-Breaking Trials from EuroPCR 2024
15 May 2024 – From EuroPCR 2024
This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid...
The ARC consensus on DCB - evidence-based DCB technology
15 May 2024 – From EuroPCR 2024
In this replay, discover why DCBs are essential in treating de novo CAD, the importance of optimal lesion preparation for long-term success, and how future trials will focus on treatment strategies rather than device comparisons, highlighting the need for further research.
LANDMARK RCT - Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial
15 May 2024 – From EuroPCR 2024
This session provides an overview of the early outcomes of the LANDMARK trial, a randomized non-inferiority trial comparing TAVI devices. It examines baseline characteristics, the significance of intermediate sizes according to MSCT recommendations, real-world representative cases from the LANDMARK RCT, insights from quantitative aortography and echocardiography...
Ahead of the curve - Innovate your treatment strategies for optimised clinical outcomes
14 May 2024 – From EuroPCR 2024
Watch this session to learn how to accurately interpret OCT-visualized dissections for an optimized PCI approach using drug-coated balloons (DCB) or drug-eluting stent (DES), to understand the critical role of sufficient and persistent sirolimus content in the vessel wall after using a sirolimus-coated balloon, to get...
Supraflex Cruz - Improving patient outcomes: from simple to complex patients
14 May 2024 – From EuroPCR 2024
Discover the remarkable performance of Supraflex Cruz in real-world clinical settings, showcasing exceptionally low event rates and demonstrating its safety and efficacy across a spectrum of high-risk patients, including the elderly and those with high bleeding risks, and delve into the ongoing TALENT and TUDEXO II...
The LANDMARK trial: early outcomes of a randomised non-inferiority trial comparing TAVI devices
15 May 2024 – From EuroPCR 2024
In this video, Christopher Cook interviews Patrick Serruys about the late-breaking clinical trial data from the LANDMARK RCT. Patrick Serruys begins by explaining the LANDMARK trial, which compares TAVI devices, and emphasizes the complexity of applying VARC-3 criteria. He highlights that the 30-day outcomes confirm the...
EuroPCR 2024 – Built by and for its participants, more than ever before
29 Mar 2024
Over 11,000 participants from around the globe are once again expected at EuroPCR – a Course tailored for interventional cardiologists, cardiac surgeons, imaging specialists, radiologists, nurses, allied professionals and other practitioners, as well as researchers, innovators and industry representatives. They will be sharing their knowledge, skills and experience on...
Essentials of lifetime management of TAVI patients
21 Nov 2023 – From PCR London Valves 2023
Consult this session if you want to learn about the next generation transcatheter heart valve technology key features, procedural and clinical benefits, to learn tips and tricks for managing bicuspid and valve-in-valve interventions, and to understand procedural and clinical relevance of intermediate and XL sizes in...
Unmet clinical need & relevance of intermediate & XL sizes in TAVI
08 Jan 2024 – From PCR London Valves 2023
In this roundtable discussion, Patrick Serruys, Andreas Baumbach, and Christian Juhl Terkelsen explore the innovative concept of intermediate sizes and extra-large valves. They introduce a new valve which is another step forward in addressing the unmet needs of the interventional cardiovascular community.
This interview was filmed at...
Next generation balloon expandable TAVR and thin strut BRS - Science and clinical update
17 May 2023 – From EuroPCR 2023
Join this session for an update on the science and clinical advancements in next-generation balloon-expandable transcatheter aortic valve replacement (TAVR) and thin strut bioresorbable scaffolds (BRS). Discover how these innovative technologies can improve clinical outcomes by exploring case-based challenging scenarios and learn effective strategies for tackling...
DEFINE FLAIR 5-year and Reveal iFR: learnings on coronary physiology
18 May 2023 – From EuroPCR 2023
Javier Escaned invites Justin Davies and Patrick Serruys to give an update on two trials presented at EuroPCR 2023: DEFINE-FLAIR 5-year follow-up and Reveal iFR.
DEFINE-FLAIR was the largest physiological study of its kind at the time, testing iFR in a non-inferior setting against FFR. The data...
Left main bifurcation treatment with Ultrathin Supraflex Cruz stent: from non-invasive angiography to invasive assessment of anatomy and physiology
16 May 2023 – From EuroPCR 2023
In this session, experience a multimodality approach, including CTA, angiography and OCT, and learn how to reestablish good hemodynamic of the bifurcation, by analyzing the case of an 81-year-old man with no risk factors, no relevant comorbidities, and no treatment, who presented with crescendo effort angina.
Clinical outcomes after TAVI: Session 1
28 Nov 2022 – From PCR London Valves 2022
Consult this session to learn more about clinical outcomes after TAVI thanks to a selection of abstracts submitted during PCR LV 2022: definition of transcatheter heart valve orientation in bicuspid aortic valve with the DA VINCI study, TAVI with latest device iterations in patients with very...
TAVI: new devices and procedural refinements
27 Nov 2022 – From PCR London Valves 2022
Consult this session dedicated to TAVI new devices and procedural refinements to learn more about Meril's Myval transcatheter heart valve, the newest EVOLUT-FX self-expanding supra-annular valve, the OctaAlign technique with the novel Myval octacor transcatheter heart valve, and more!
Definitions and standardized endpoints for treatment of coronary bifurcations: Bif-ARC
03 Jun 2022
The current consensus document, which is prepared by the collaboration of the most renowned interventional cardiology societies and academic research organizations, aims to provide standardized definitions for bifurcation lesions.
Reviewer
Simplifying complex coronary interventions by adopting angiography-based physiology and a healing-targeted DES
19 May 2022 – From EuroPCR 2022
Consult this session to learn how to apply angio-based physiology to optimise patient selection for PCI, to discuss the impact of a healing-targeted DES on outcomes and DAPT duration, as well as to learn about the HT Supreme DES implantations in the (ongoing) QFR-guided, PIONEER IV trial.
CT coronary angiography vs invasive coronary angiography - What you need to know so you don't miss the bus!
18 May 2022 – From EuroPCR 2022
Thanks to this EuroPCR 2022 session, learn about the advantages and drawbacks of coronary CT, how coronary CT available prior to PCI can inform and lighten this procedure, and how coronary CT prior to operation can help patients who eventually undergo bypass surgery.
Bifurcation PCI: new consensus from the Academic Research Consortium and the European Bifurcation Club
18 May 2022 – From EuroPCR 2022
Among the many objectives of this session, learn how to define coronary bifurcations and trifurcations, how to classify coronary bifurcation and trifurcation lesions, how to use functional assessment in a bifurcation lesion, or how to understand the standardized assessment of the SB relevance according to the...
How to select three-vessel disease patients eligible for PCI and guide the treatment by angiography-derived physiology
18 May 2022 – From EuroPCR 2022
What is angiographic SYNTAX score? Are 3VD all the same? What do ESC guidelines recommend? You will find answers to these questions, and many more, in this EuroPCR 2022 session, through which you will learn how to identify the right patient for three-vessel PCI, select the lesions to be...
The ability to transform coronary artery disease treatment: innovative nanotechnology-based sirolimus DES and DCB platforms
18 May 2022 – From EuroPCR 2022
Alexandre Abizaid, Marco Valgimigli, Fazila Malik, Luca Testa, Patrick W. Serruys, Damiano Regazzoli, Kumar Prathap, and Sandeep Basavarajaiah take turns in this session to discuss two innovative technologies: a stent platform with nanotechnology and a novel drug-coated balloon (DCB). These novel technologies both have unique features...
How to use coronary CT imaging and physiology for multivessel disease
18 May 2022 – From EuroPCR 2022
How can imaging and physiology help treat this 77-year-old female patient, ex-smoker, with dyslipidemia, stable angina, and EF at 60 %, or this 67-year-old male patient with HTN, CCS class III, and LV EF at 61 %? The answers in this EuroPCR 2022 session.
Clinical decision based on coronary physiology: where do we stand in 2022?
17 May 2022 – From EuroPCR 2022
Watch this EuroPCR 2022 session if you want to know the latest updates on integrating physiology into optimal revascularization in the cathlab: improvements in wire-based technologies, QFR from online or offline CAG, CT angio coupled with FFR, and physiology-guided vs angio-guided revascularization in ACS.
Sirolimus coated balloon and coronary artery disease: expanding the treatment indications
17 May 2022 – From EuroPCR 2022
Through a case presentation, as well as upcoming studies and rationale for the Food and Drug Administration, the aim of this EuroPCR 2022 session is to help you answer the following questions: how can the use of a sirolimus-coated DCB be expanded in new and challenging treatment indications? Why is...
